Hormonal
Semaglutide (2.4 mg once-weekly subcutaneous) significantly reduces body weight in adults with obesity or overweight with comorbidities compared to placebo.
For adults with obesity or overweight who have at least one weight-related health issue (like high blood pressure or cholesterol), a once-weekly injection of semaglutide (2.4 mg) combined with lifestyle changes can lead to significant, sustained weight loss (averaging nearly 15% of body weight in trials). While gastrointestinal side effects like nausea are common, they often subside, and starting with a lower dose can help your body adjust.
At week 68, the mean body weight change was highly significant in the semaglutide group vs. the placebo group (-14.9 vs. -2.4%; ETD, -12.4%; P<0.001).
Why this rating
Based on Phase III randomized, double-blind, placebo-controlled trials (STEP program).
Source
Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
Mariana Cornelia Tilinca et al. · Experimental and Therapeutic Medicine · 2021
DOI 10.3892/etm.2021.10601
More from this paper
- Semaglutide (0.5-1.0 mg once-weekly subcutaneous) lowers HbA1c and reduces body weight more effectively than other common GLP-1 RAs (exenatide, dulaglutide, liraglutide) and SGLT-2 inhibitors (canagliflozin) in Type 2 Diabetes.Strong
- Semaglutide (subcutaneous and oral) demonstrates cardiovascular safety (non-inferiority) and potential renal benefits in high-risk Type 2 Diabetes patients, though it may increase retinopathy complications.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →